Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
Resomelagon (0-1000 μM; 8 minutes; HEK293A cells) stimulates Ca2+ and phosphorylates ERK1/2 to enhance melanobasin signaling [1]. Resomelagon possesses anti-inflammatory properties (1 nM; 30 min; peritoneal macrophages).
|
---|---|
ln Vivo |
Resomelagon (zero to ten milligrams per kilogram; intraperitoneal, intravenous, intravenous; 24-hour; furnished with electrodes for both BALB/c and C57BL/6J wild-type (WT) and WT cells) facilitates the resolution of acute inflammation in the body [1]. Mice's arthritis is reduced by resomelagon (25) - 50 mg/kg; mouse; once daily for 8 days; male C57BL/6J wild-type (WT) and BALB/c mice [1].
|
Cell Assay |
Western Blot analysis [1]
Cell Types: HEK293A Cell Tested Concentrations: 0-1000 μM Incubation Duration: 8 min Experimental Results: ERK1/2 phosphorylation in dose- Increases expression and inhibits TNF-α release and cell vomiting [1]. Dependence method. |
Animal Protocol |
Animal/Disease Models: Male C57BL/6J wild-type (WT) and balb/c (Bagg ALBino) mouse [1]
Doses: 0, 0.1, 1, and 10 mg/kg Route of Administration: po (po (oral gavage)) intraperitoneal, and intravenous (iv) (iv)injection; 24-hour Experimental Results: Inhibits neutrophil and monocyte infiltration in a dose-dependent manner. Animal/Disease Models: Male C57BL/6J wild-type (WT) and balb/c (Bagg ALBino) mouse [1] Doses: 25 and 50 mg/kg Route of Administration: Oral; daily; for 8 days Experimental Results: Reduction in all joints measured symptoms of inflammation, including clinical score (-42%), paw swelling (-87%), proportion of animals with all four paws affected (-50%), and severity of inflammation (-70%). |
References |
[1]. Montero-Melendez T, et, al. Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects. J Immunol. 2015 Apr 1;194(7):3381-8.
[2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical |
Molecular Formula |
C14H14N6O2
|
---|---|
Molecular Weight |
298.30
|
CAS # |
1809420-71-0
|
Related CAS # |
Resomelagon acetate;1809420-72-1
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
N1(C2C=CC=CC=2[N+]([O-])=O)C(/C=C/C=N/NC(N)=N)=CC=C1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3523 mL | 16.7616 mL | 33.5233 mL | |
5 mM | 0.6705 mL | 3.3523 mL | 6.7047 mL | |
10 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.